MMP7 expression regulated by endocrine therapy in ER-positive colon cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Fang, Yu Jing ^a   Pan, Zhi Zhong ^a   Li, Li Ren ^a   Lu, Zhen Hai ^a   Zhang, Li Yi ^a   Wan, De Sen ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR BETA; FLUOROURACIL; MATRILYSIN; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CELL ASSAY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; COLON TUMOR; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; ESTROGEN RECEPTOR BETA; FLOW CYTOMETRY; FLUOROURACIL; HT29 CELLS; HUMANS; MATRIX METALLOPROTEINASE 7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN;

EID: 70350463894     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-132     Document Type: Article

References (37)

1. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA: a Cancer Journal for Clinicians 2005 55 74 108 10.3322/canjclin.55.2.74 15761078
2. Colorectal cancer. R Midgley D Kerr, Lancet 1999 353 391 399 10.1016/S0140-6736(98)07127-X 9950460
3. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. W Scheithauer H Rosen GV Kornek C Sebesta D Depisch, BMJ 1993 306 752 755 10.1136/bmj.306.6880.752 7683942
4. Hepatic resection for colorectal metastases: value for risk scoring systems? S Zakaria JH Donohue FG Que MB Farnell CD Schleck DM Ilstrup DM Nagorney, Annals of Surgery 2007 246 183 191 10.1097/SLA.0b013e3180603039 17667495
5. Metastases of prostate cancer express estrogen receptor-beta. JS Lai LG Brown LD True SJ Hawley RB Etzioni CS Higano SM Ho RL Vessella E Corey, Urology 2004 64 814 820 10.1016/j.urology.2004.05.036 15491740
6. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. YF Hou ST Yuan HC Li J Wu JS Lu G Liu LJ Lu ZZ Shen J Ding ZM Shao, Oncogene 2004 23 5799 5806 10.1038/sj.onc.1207765 15208676
7. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. V Guerini D Sau E Scaccianoce P Rusmini P Ciana A Maggi PG Martini BS Katzenellenbogen L Martini M Motta A Poletti, Cancer Research 2005 65 5445 5453 10.1158/0008-5472.CAN-04-1941 15958594
8. Cloning of a novel receptor expressed in rat prostate and ovary. GG Kuiper E Enmark M Pelto-Huikko S Nilsson JA Gustafsson, Proceedings of the National Academy of Sciences of the United States of America 1996 93 5925 5930 10.1073/pnas.93.12.5925 8650195
9. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. D Witte M Chirala A Younes Y Li M Younes, Human Pathology 2001 32 940 944 10.1053/hupa.2001.27117 11567223
10. Functional estrogen receptor beta in colon cancer cells. G Fiorelli L Picariello V Martineti F Tonelli ML Brandi, Biochemical & Biophysical Research Communications 1999 261 521 527 10.1006/bbrc.1999.1062 (Pubitemid 29392509)
11. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. Y Qiu CE Waters AE Lewis MJ Langman MC Eggo, Journal of Endocrinology 2002 174 369 377 10.1677/joe.0.1740369 12208656
12. Selective loss of estrogen receptor beta in malignant human colon. EF Foley AA Jazaeri MA Shupnik O Jazaeri LW Rice, Cancer Research 2000 60 245 248 10667568
13. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. O Imamov A Morani GJ Shim Y Omoto C Thulin-Andersson M Warner JA Gustafsson, Proceedings of the National Academy of Sciences of the United States of America 2004 101 9375 9380 15187231 10.1073/pnas.0403041101
14. Mechanisms of estrogen action. S Nilsson S Makela E Treuter M Tujague J Thomsen G Andersson E Enmark K Pettersson M Warner JA Gustafsson, Physiological Reviews 2001 81 1535 1565 11581496
15. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. C Forster S Makela A Warri S Kietz D Becker K Hultenby M Warner JA Gustafsson, Proceedings of the National Academy of Sciences of the United States of America 2002 99 15578 15583 12438700 10.1073/pnas.192561299
16. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Z Weihua S Makela LC Andersson S Salmi S Saji JI Webster EV Jensen S Nilsson M Warner JA Gustafsson, Proceedings of the National Academy of Sciences of the United States of America 2001 98 6330 6335 11371645 10.1073/pnas.111150898
17. Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. GJ Shim L Wang S Andersson N Nagy LL Kis Q Zhang S Makela M Warner JA Gustafsson, Proceedings of the National Academy of Sciences of the United States of America 2003 100 6694 6699 12740446 10.1073/pnas.0731830100
18. Steroid hormone receptors: many actors in search of a plot. M Beato P Herrlich G Schutz, Cell 1995 83 851 857 10.1016/0092-8674(95)90201-5 8521509
19. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. K Paech P Webb GG Kuiper S Nilsson J Gustafsson PJ Kushner TS Scanlan, Science 1997 277 1508 1510 10.1126/science.277.5331.1508 9278514
20. Oestradiol and tamoxifen inhibit murine Colon 38 cancer growth and increase the cytotoxic effect of fluorouracil. E Motylewska H Lawnicka G Melen-Mucha, Endokrynologia Polska 2007 58 426 434 18058739
21. Role of matrix metalloproteinases (MMPs) in colorectal cancer. S Zucker J Vacirca, Cancer & Metastasis Reviews 2004 23 101 117 10.1023/A: 1025867130437 15000152
22. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. S Malhotra E Newman D Eisenberg J Scholes R Wieczorek P Mignatti P Shamamian, Diseases of the Colon & Rectum 2002 45 537 543 10.1007/s10350-004-6236-7
23. Structural determinants of procryptdin recognition and cleavage by matrix metalloproteinase-7. Y Shirafuji H Tanabe DP Satchell A Henschen-Edman CL Wilson AJ Ouellette, Journal of Biological Chemistry 2003 278 7910 7919 10.1074/jbc.M210600200 12482850
24. Relationship between matrix metalloproteinase-7 and pit pattern in early stage colorectal cancer. Y Saitoh H Yanai S Higaki H Nohara T Yoshida K Okita, Gastrointestinal Endoscopy 2004 59 385 392 10.1016/S0016-5107(03)02817-7 14997136
25. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. AV Ougolkov K Yamashita M Mai T Minamoto, Gastroenterology 2002 122 60 71 10.1053/gast.2002.30306 11781281
26. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. K Miyazaki Y Hattori F Umenishi H Yasumitsu M Umeda, Cancer Research 1990 50 7758 7764 2253219
27. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Y Adachi F Itoh H Yamamoto S Iku K Matsuno Y Arimura K Imai, Tumour Biology 2001 22 247 253 10.1159/000050623 11399950
28. Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. H Yamamoto S Iku Y Adachi A Imsumran H Taniguchi K Nosho Y Min S Horiuchi M Yoshida F Itoh K Imai, Journal of Pathology 2003 199 176 184 10.1002/path.1277 12533830
29. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. ZS Zeng WP Shu AM Cohen JG Guillem, Clinical Cancer Research 2002 8 144 148 11801551
30. Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. GI Gorodeski, Endocrinology 2007 148 218 231 17038551 10.1210/en.2006-1120
31. A pharmacological review of selective oestrogen receptor modulators. SR Goldstein S Siddhanti AV Ciaccia L Plouffe Jr, Human Reproduction Update 2000 6 212 224 10.1093/humupd/6.3.212 10874566
32. Polyamines are necessary for normal expression of the transforming growth factor-beta gene during cell migration. JY Wang MJ Viar J Li HJ Shi SA McCormack LR Johnson, American Journal of Physiology 1997 272 713 720 9142900
33. Expression of the transforming growth factor-beta gene during growth inhibition following polyamine depletion. AR Patel J Li BL Bass JY Wang, American Journal of Physiology 1998 275 590 598 9688614
34. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. HH Hsu SF Cheng CC Wu CH Chu YJ Weng CS Lin SD Lee HC Wu CY Huang WW Kuo, Chinese Journal of Physiology 2006 49 110 116 16830793
35. Role of matrix metalloproteinases in colorectal carcinogenesis. MJ Heslin J Yan MR Johnson H Weiss RB Diasio MM Urist, Annals of Surgery 2001 233 786 792 11371737 10.1097/00000658-200106000-00008
36. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. HC Crawford BM Fingleton LA Rudolph-Owen KJ Goss B Rubinfeld P Polakis LM Matrisian, Oncogene 1999 18 2883 2891 10.1038/sj.onc.1202627 10362259
37. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. MF Leeman S Curran GI Murray, Journal of Pathology 2003 201 528 534 10.1002/path.1466 14648655